BRPI0210903B8 - método de diagnóstico ou prognóstico de principais patógenos bacterianos respiratórios em um indivíduo - Google Patents

método de diagnóstico ou prognóstico de principais patógenos bacterianos respiratórios em um indivíduo

Info

Publication number
BRPI0210903B8
BRPI0210903B8 BRPI0210903A BR0210903A BRPI0210903B8 BR PI0210903 B8 BRPI0210903 B8 BR PI0210903B8 BR PI0210903 A BRPI0210903 A BR PI0210903A BR 0210903 A BR0210903 A BR 0210903A BR PI0210903 B8 BRPI0210903 B8 BR PI0210903B8
Authority
BR
Brazil
Prior art keywords
prognosis
diagnosis
individual
iii
subject
Prior art date
Application number
BRPI0210903A
Other languages
English (en)
Other versions
BRPI0210903B1 (pt
BR0210903A (pt
Inventor
Eugen-Olsen Jesper
Original Assignee
Virogates Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogates Aps filed Critical Virogates Aps
Publication of BR0210903A publication Critical patent/BR0210903A/pt
Publication of BRPI0210903B1 publication Critical patent/BRPI0210903B1/pt
Publication of BRPI0210903B8 publication Critical patent/BRPI0210903B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"método de diagnóstico ou prognóstico de principais patógenos bacterianos respiratórios em um indivíduo". um método de diagnóstico e/ou prognóstico de infecções bacterianas respiratórias em um indivíduo compreendendo as etapas de (a) realizar in vitro uma medição do nível de um ou mais marcadores na forma de (i) receptor de ativador de plasminogênio de uroquinase (upar), (ii) receptor de ativador de plasminogênio de uroquinase solúvel (supar), e/ou (iii) um ou mais produtos de degradação de (i) ou (ii), em uma amostra de fluido biológico oriundo de um indivíduo, e (b) usar o valor de medição obtido para avaliar o estado do indivíduo. especialmente infecções por streptococcus pneumoniae e mycobacterium tuberculosis podem ser diagnosticadas e/ou prognosticadas.
BRPI0210903A 2001-05-18 2002-05-21 método de diagnóstico ou prognóstico de principais patógenos bacterianos respiratórios em um indivíduo BRPI0210903B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100799 2001-05-18
PCT/DK2002/000341 WO2002095411A1 (en) 2001-05-18 2002-05-21 A method of diagnosing or prognosticating major respiratory bacterial pathogens in a subject

Publications (3)

Publication Number Publication Date
BR0210903A BR0210903A (pt) 2004-06-08
BRPI0210903B1 BRPI0210903B1 (pt) 2017-01-17
BRPI0210903B8 true BRPI0210903B8 (pt) 2021-07-27

Family

ID=8160511

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210903A BRPI0210903B8 (pt) 2001-05-18 2002-05-21 método de diagnóstico ou prognóstico de principais patógenos bacterianos respiratórios em um indivíduo

Country Status (11)

Country Link
US (1) US7399602B2 (pt)
EP (1) EP1405076B1 (pt)
CN (1) CN100340858C (pt)
AT (1) ATE479097T1 (pt)
BR (1) BRPI0210903B8 (pt)
DE (1) DE60237448D1 (pt)
DK (1) DK1405076T3 (pt)
EA (1) EA005776B1 (pt)
ES (1) ES2351690T3 (pt)
WO (1) WO2002095411A1 (pt)
ZA (1) ZA200309770B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2291226T3 (es) 1999-11-25 2008-03-01 Jesper Eugen-Olsen Un metodo de diagnostico o prognosis de infeccion por vih en un sujeto.
US20060084184A1 (en) * 2004-10-19 2006-04-20 Renovar Incorporated Reagents for urine-based immunological assays
EP2226635B1 (en) * 2007-12-28 2013-03-13 BL Co., Ltd Immunodetection assay for mycobacterium tuberculosis complex
EP2711710B1 (en) * 2011-05-19 2017-04-26 Mochida Pharmaceutical Co., Ltd. Diagnosis of respiratory tract infectious diseases using urine specimens
GB201211982D0 (en) * 2012-07-05 2012-08-22 Isis Innovation Biomarker
CN106461674A (zh) * 2014-04-15 2017-02-22 斯坦陵布什大学 一种用于诊断结核性脑膜炎的方法
US10094833B2 (en) 2014-08-08 2018-10-09 Randox Laboratories Limited Method and kit for detecting bacterial infection
CN106556703A (zh) * 2016-10-18 2017-04-05 上海凯璟生物科技有限公司 一种慢性肾脏病标志物suPAR检测试剂盒和制备方法
RU2659384C1 (ru) * 2017-07-10 2018-06-29 Федеральное государственное бюджетное учреждение "Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства" Способ раннего прогнозирования характера течения острой респираторной инфекции у детей
GB201802795D0 (en) * 2018-02-21 2018-04-04 Virogates As Patient assessment method
FR3080185A1 (fr) * 2018-04-16 2019-10-18 Biomerieux Evaluation du risque de complication chez un patient suspecte d'avoir une infection ayant un score sofa inferieur a deux
CN115516314A (zh) * 2020-04-08 2022-12-23 维罗盖茨有限公司 Sars-cov-2感染风险评估方法
AU2021292488A1 (en) * 2020-06-15 2023-02-02 Monopar Therapeutics, Inc. Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (uPAR) for treatment of severe COVID-19 disease
RU2765744C2 (ru) * 2020-07-20 2022-02-02 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ определения вероятности летального исхода на основании жалоб у больного туберкулезом с ВИЧ-инфекцией при поступлении в стационар Федеральной службы исполнения наказаний РФ
CN113295874B (zh) * 2021-05-25 2022-03-04 广东源心再生医学有限公司 一种用于瓣膜性心脏病辅助诊断的新型标志物、辅助诊断的产品

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845026A (en) * 1985-12-03 1989-07-04 T Cell Sciences, Inc. Assay systems for detecting cell-free T cell antigen receptor related molecules and the clinical utilities of the assays
US5459078A (en) * 1988-01-29 1995-10-17 Abbott Laboratories Methods and reagents for performing ion-capture digoxin assays
US6406873B2 (en) 1998-01-26 2002-06-18 Biotech Australia Pty Ltd PAI-2 and T-PA as diagnostic markers of periodontal disease
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
DE19840671A1 (de) 1998-08-26 2000-03-02 Stiftung Tumorbank Basel Verfahren zur Diagnose von Rezidiven bei nodal-negativem Brustkrebs
CA2384295A1 (en) 1999-04-28 2000-11-02 Yahia Gawad Method for determining plasminogen activator inhibitor
ES2291226T3 (es) 1999-11-25 2008-03-01 Jesper Eugen-Olsen Un metodo de diagnostico o prognosis de infeccion por vih en un sujeto.

Also Published As

Publication number Publication date
ZA200309770B (en) 2004-09-28
EP1405076A1 (en) 2004-04-07
WO2002095411A1 (en) 2002-11-28
EA005776B1 (ru) 2005-06-30
CN1723394A (zh) 2006-01-18
BRPI0210903B1 (pt) 2017-01-17
DE60237448D1 (de) 2010-10-07
BR0210903A (pt) 2004-06-08
CN100340858C (zh) 2007-10-03
US20050100961A1 (en) 2005-05-12
ES2351690T3 (es) 2011-02-09
EA200301271A1 (ru) 2004-06-24
ATE479097T1 (de) 2010-09-15
DK1405076T3 (da) 2011-01-03
EP1405076B1 (en) 2010-08-25
US7399602B2 (en) 2008-07-15

Similar Documents

Publication Publication Date Title
BRPI0210903B8 (pt) método de diagnóstico ou prognóstico de principais patógenos bacterianos respiratórios em um indivíduo
AU2002341191A1 (en) Diagnosis of clinical infection of a wound
Belibasakis et al. Soluble triggering receptor expressed on myeloid cells 1 (sTREM‐1) in gingival crevicular fluid: association with clinical and microbiologic parameters
GB2461410A (en) Soluble urokinase plasminogen activator receptor (SUPAR) as marker for diseases
AU6680098A (en) Device and method for determining analyte levels
AU2002327308A1 (en) Methods for evaluating pathologic conditions using extracellular rna
Oettinger‐Barak et al. Clinical and microbiological characterization of localized aggressive periodontitis: a cohort study
CA2445450A1 (en) Blood flow monitor for shock and resuscitation
WO2022056313A3 (en) Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
EP1221620A3 (en) Method for performing activated clotting time test with reduced sensitivity to the presence of aprotinin and for assessing aprotinin sensitivity
WO2002014537A3 (en) Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
AP1623A (en) A method of diagnosing of prognosticating HIV infection in a subject.
Ventetuolo et al. Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis
ATE529743T1 (de) Verfahren und kits zur tumorigenizitätsdiagnose
GB0420774D0 (en) Wound treatment system
EP1362601B8 (en) Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression
Nakamura et al. Changes of parameters in fibrinolytic system caused by mental stress
WO2002103059A3 (en) Innate immunity markers for rapid diagnosis of infectious diseases
NO20003766L (no) PAI-2 og t-PA som diagnostiske markører for periodontal sykdom
DE60232069D1 (de) Formen prostataspezifischer antigene und verfahren zu deren nachweis
Faraj et al. Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
DE60144027D1 (de) 5t4 rna in plasma und serum als marker für neoplastische erkrankungen
DE60029939D1 (de) Diagnosisverfahren für whipples krankheit
DE60221883D1 (de) Screeningverfahren für einen auf die zellwand wirkenden arzneistoff
WO2002056666A3 (en) A method of detecting ultrasound contrast agent in soft tissue, and quantitating blood perfusion through regions of tissue

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/01/2017, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/05/2002, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 21/05/2022